PhenomeX Inc. (CELL)

Market Cap	41.67M
Revenue (ttm)	76.91M
Net Income (ttm)	-100.03M
Shares Out	75.76M
EPS (ttm)	-1.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	961,556
Open	0.540
Previous Close	0.522
Day's Range	0.525 - 0.570
52-Week Range	0.508 - 6.110
Beta	n/a
Analysts	Hold
Price Target	3.00 (+445.46%)
Earnings Date	May 11, 2023

About CELL

PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease. The company's platforms are used by researchers worldwide, including pharmaceutical companies and comprehensive cancer centers. PhenomeX Inc. is headquartered in Emeryville, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 17, 2020
• Employees: 285
• Stock Exchange: NASDAQ
• Ticker Symbol: CELL

Financial Performance

In 2022, PhenomeX's revenue was $78.60 million, a decrease of -7.96% compared to the previous year's $85.39 million. Losses were -$98.04 million, 36.7% more than in 2021.

Analyst Forecast

According to one analyst, the rating for CELL stock is "Hold" and the 12-month stock price forecast is $3.0.

Price Target

$3.0

(445.46% upside)

Analyst Consensus: Hold